MISSISSAUGA, ON, May 18, 2012 /PRNewswire/ - Covalon Technologies
Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical
technologies company, today announced it will be showcasing
its advanced medical coating capabilities, including its
SilverCoatTM Antimicrobial Silicone Foley Catheter as
well as its recently FDA cleared IV Clear™ antimicrobial silicone
adhesive film dressing from May
19th to May
23rd at the American Urological Association 2012
Annual Meeting ("AUA") in Atlanta,
Georgia.
"We are looking forward to presenting our SilverCoat™
Antimicrobial Silicone Foley Catheter, with its lubricious and
antimicrobial coating at the AUA," said Brian Pedlar, Covalon's Chief Executive Officer.
"We have demonstrated that our antimicrobial coating outperforms
market-leading silver coated Foley catheters in killing the
bacteria most commonly associated with urinary tract infections.
The AUA provides Covalon with a great opportunity to showcase our
urological care products to an international audience, including
close to three hundred leading manufacturers, wholesalers and
distributors."
Urinary tract infections have been identified by the United States Center for Disease Control
as the most common type of healthcare associated infection, of
which 75% are associated with a urinary catheter, often referred to
as CAUTIs. The Centers for MediCare and Medicaid Services are
no longer reimbursing medical institutions for the treatment of
CAUTIs.
Now in its 107th year, the AUA Annual Meeting is the largest
gathering of urologists in the world, providing unparalleled access
to groundbreaking research, new guidelines and the latest advances
in urologic medicine.
Covalon will also be showcasing its advanced wound and
antimicrobial silicone adhesive technology. These exciting new
products will be available for license or distribution, following
regulatory clearance to our growing domestic and international
distribution channels and to medical product companies who are
looking to license breakthrough new products.
To learn more about Covalon's products and services, please
visit us at booth 3756 in the Georgia World Congress Center from
May 19th to
23rd or contact Brian
Pedlar, CEO, Covalon Technologies Ltd. at
bpedlar@covalon.com.
About Covalon
Covalon Technologies Ltd. researches, develops and
commercializes new healthcare technologies that help save lives
around the world. Covalon's patented technologies, products and
services address the advanced healthcare needs of medical device
companies, healthcare providers and individual consumers. Covalon's
technologies are used to prevent, detect and manage medical
conditions in specialty areas such as wound care, tissue repair,
infection control, disease management, medical device coatings and
biocompatibility. To learn more about Covalon, visit our website at
www.covalon.com Follow us on Twitter @covalon
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release contains forward-looking statements which
reflect the Company's current expectations regarding future events.
The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend" and statements that an event or
result "may", "will", "should", "could" or "might" occur or be
achieved and other similar expressions. These forward-looking
statements involve risk and uncertainties, including the difficulty
in predicting product approvals, acceptance of and demands for new
products, the impact of the products and pricing strategies of
competitors, delays in developing and launching new products, the
regulatory environment, fluctuations in operating results and other
risks, any of which could cause results, performance, or
achievements to differ materially from the results discussed or
implied in the forward-looking statements. Many risks are inherent
in the industry; others are more specific to the Company. Investors
should consult the Company's ongoing quarterly filings for
additional information on risks and uncertainties relating to these
forward-looking statements. Investors should not place undue
reliance on any forward-looking statements. The Company assumes no
obligation to update or alter any forward-looking statements
whether as a result of new information, further events or
otherwise.
SOURCE Covalon Technologies Ltd.